Recent real-world and implementation data support the effectiveness of the long-acting injectable HIV treatment combination Vocabria (cabotegravir) and Rekambys (rilpivirine), jointly referred to as CAB+RPV LA. These findings, derived from clinical practice and observational studies, reinforce the therapeutic value of this dosing strategy for maintaining viral suppression in people living with HIV.
CAB+RPV LA is administered as a monthly or bimonthly injection, offering an alternative to daily oral antiretroviral therapies. This regimen has been shown to maintain viral suppression with fewer chances of missed doses, which is often a concern with daily-pill regimens.
Implementation studies further highlight the potential of long-acting CAB+RPV LA to improve the quality of life for patients by reducing the treatment burden. Healthcare providers have also reported high levels of satisfaction with the injectable regimen, noting ease of administration and support for patient adherence. Real-world data indicate the therapy is effective across diverse populations and care environments, aligning with results from controlled clinical trials.
The adoption of long-acting regimens like CAB+RPV LA marks a significant step forward in the patient-centered management of HIV, underpinning the importance of flexible and efficient treatment options in achieving long-term viral suppression and improving outcomes for people living with HIV.
Source: https:// – Courtesy of the original publisher.
